B-cell lymphoma 2 (Bcl-2) Inhibitor AT-101 leads to potentiation of radiotherapy-dependent apoptosis in head and neck squamous cell carcinoma in vitro, which further encourages the use of AT-101 in Bcl-2 expressing malignancies. The gene discussed is BCL2; the disease is head and neck squamous cell carcinoma.